Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.53 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9136766 | 0.85 | NLRP3 (0.62) | NLRP3SMN1; SMN2SOAT1SOAT2MAPK1 | |
| SCHEMBL9843936 | 0.84 | SMN1; SMN2 (0.77) | NLRP3SMN1; SMN2SOAT1SOAT2KMT2A | |
| SCHEMBL28188485 | 0.83 | NLRP3 (0.81) | NLRP3SMN1; SMN2MAPK1KMT2AMEN1 | |
| SCHEMBL20702692 | 0.82 | NLRP3 (1.00) | NLRP3SMN1; SMN2MAPK1KMT2ALMNA | |
| SCHEMBL13328399 | 0.81 | NLRP3 (0.58) | NLRP3SMN1; SMN2SOAT1SOAT2MAPK1 | |
| SCHEMBL6887530 | 0.81 | NLRP3 (0.67) | NLRP3MAPK1KMT2AMEN1LMNA | |
| SCHEMBL28229524 | 0.80 | SMN1; SMN2 (0.72) | NLRP3SMN1; SMN2SOAT1SOAT2MAPK1 | |
| SCHEMBL11267236 | 0.80 | NLRP3 (0.63) | NLRP3SMN1; SMN2MAPK1KMT2ALMNA | |
| SCHEMBL2148218 | 0.79 | SMN1; SMN2 (0.70) | NLRP3SMN1; SMN2SOAT1SOAT2KMT2A | |
| SCHEMBL8962550 | 0.78 | NLRP3 (0.58) | NLRP3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981936-B2 | Crystalline ACAT inhibitor | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100324145-A1 | Crystalline ACAT Inhibitor | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-12-23 | — | — | US | disclosed |
| US-7622610-B2 | Topical, oily skin disorders such as acne; N-benzyl-N'-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide | GRACEWAY PHARMACEUTICALS, LLC (US) | 2009-11-24 | — | — | US | disclosed |
| CN-101111470-A | Crystalline acat (acyl-coa:cholesterol o-acyltransferase) inhibitor | WARNER LAMBERT CO (US) | 2008-01-23 | — | — | CN | disclosed |
| EP-1856029-A1 | CRYSTALLINE ACAT INHIBITOR | Warner-Lambert Company LLC (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090274-A1 | CRYSTALLINE ACAT INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189697-A1 | Crystalline ACAT inhibitor | WARNER-LAMBERT COMPANY LLC | 2006-08-24 | — | — | US | disclosed |
| WO-1991015464-A1 | AMIDE ESTER ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1991-10-17 | — | — | WO | disclosed |
| EP-0433662-A2 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189697-A1 | Crystalline ACAT inhibitor | ACAT2, ACAT1, ACACA | NLRP3 2809/4885SMN1; SMN2 4094/4885SOAT1 36/4885 |
| US-20100324145-A1 | Crystalline ACAT Inhibitor | ACAT2, ACAT1, ACACA | NLRP3 2809/4885SMN1; SMN2 4094/4885SOAT1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.